earnings
confidence high
sentiment neutral
materiality 0.75
Ashland Q1 sales down 5% to $386M; narrows FY2026 EBITDA guidance to $400–420M
ASHLAND INC.
2026-Q1 EPS reported
-$0.26
revenue$386,000,000
- Net loss of $12M (($0.26)/diluted share); Adjusted EPS excl. intangibles amortization $0.26.
- Adjusted EBITDA of $58M (15% margin), down 5% YoY; Avoca divestiture reduced sales ~$10M.
- Calvert City startup delay and weather disruptions caused ~$10M Adjusted EBITDA hit, isolated to Q2.
- Life Sciences grew YoY; Personal Care and Specialty Additives declined; pricing down 2%.
- Cash flow from ops $125M (including $103M tax refund); Ongoing Free Cash Flow $26M.